Standard BioTools
LAB
100 hedge funds and large institutions have $1.02B invested in Standard BioTools in 2014 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 43 increasing their positions, 28 reducing their positions, and 19 closing their positions.
54% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 28
46% more capital invested
Capital invested by funds: $702M → $1.02B (+$322M)
11% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 19
1% more funds holding
Funds holding: 99 → 100 (+1)
15% less call options, than puts
Call options by funds: $2.06M | Put options by funds: $2.42M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$12.5M |
| 2 |
JP Morgan Chase
New York
|
+$11.7M |
| 3 |
Lazard Asset Management
New York
|
+$7.33M |
| 4 |
RIM
RS Investment Management
San Francisco,
California
|
+$7.27M |
| 5 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$6.27M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ZCI
Zevenbergen Capital Investments
Edmonds,
Washington
|
-$11.2M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$9.39M |
| 3 |
CGI
CI Global Investments
Oakland,
California
|
-$7.52M |
| 4 |
O
OppenheimerFunds
New York
|
-$3.63M |
| 5 |
Millennium Management
New York
|
-$3.56M |
LAB Hedge Fund Activity: Q4 2014 in Review
100 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in Standard BioTools (LAB) for Q4 2014, worth a combined $1.02B — up 46% from $702M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new LAB positions and 19 closed out — a net gain of 2 holders — while 43 added to existing stakes and 28 trimmed.
The largest buyer was Lord, Abbett & Co, adding an estimated $12.5M. The largest seller was Zevenbergen Capital Investments, exiting entirely with an estimated $11.2M sold.
- 100 institutional investors held Standard BioTools (LAB) as of Q4 2014, up from 99 in Q3 2014.
- Funds reported $1.02B of Standard BioTools stock for Q4 2014, up 46% quarter-over-quarter.
- 21 funds opened new Standard BioTools positions in Q4 2014 and 19 closed out, a net change of +2 holders.
- The largest Standard BioTools buyer in Q4 2014 was Lord, Abbett & Co, an estimated $12.5M added.
- The largest Standard BioTools seller in Q4 2014 was Zevenbergen Capital Investments, an estimated $11.2M sold.
Based on aggregated 13F filings for Q4 2014.